ArticleCancer cell international2025
Salivary metabolic profile landscape for gastric cancer screening: a metabolomic approach.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01420588 (Study of the Exhaled Breath and Salivary Metabolites of Patients With Malignant or Benign Gasctric Lesions), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Exhaled Breath and Salivary Metabolites of Patients With Malignant or Benign Gasctric Lesions
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study employed non-targeted liquid chromatography-mass spectrometry (LC-MS) to investigate the salivary metabolomic profiles of 177 participants, including 147 patients with gastric cancer (GC) and 30 controls with common gastritis. Following rigorous quality control measures, a total of 333 high-confidence metabolites were identified from an initial pool of 368 positive-mode metabolites and 178 negative-mode metabolites. Principal component analysis (PCA) and linear discriminant analysis (LDA) revealed significant differences between the GC and control groups, with stage I GC clearly distinguishable from more advanced stages. Differential metabolite screening was conducted using partial least squares discriminant analysis (PLS-DA) in conjunction with t-tests and fold-change analysis. After controlling for confounding factors such as age, smoking, and alcohol use, 38 salivary metabolites were identified as potential diagnostic markers. Notably, the univariate and multivariate diagnostic models demonstrated excellent discriminative performance in distinguishing GC patients from controls. PLS-DA validated by permutation testing, along with univariate and multivariate ROC analyses, exhibited excellent classification performance based on the 38 salivary metabolites. Metabolic analysis revealed significant downregulation of purines, pyrimidines, amino acids, and carbohydrates in the saliva of GC patients, while sebacic acid and GABA were found to be upregulated. Tyrosine was identified as the most significantly altered metabolite between early and advanced stages of GC. These findings underscore the substantial impact of gastric cancer on the salivary metabolome and suggest the potential of saliva as a promising tool for mass screening of GC.Trial registration DGLES, NCT01420588, Registered 19 August 2011, https://clinicaltrials.gov/ct2/show/NCT01420588 .
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.